PSD-95 protects synapses from β-amyloid

Beta-amyloid (A beta) depresses excitatory synapses by a poorly understood mechanism requiring NMDA receptor (NMDAR) function. Here, we show that increased PSD-95, a major synaptic scaffolding molecule, blocks the effects of A beta on synapses. The protective effect persists in tissue lacking the AMPA receptor subunit GluA1, which prevents the confounding synaptic potentiation by increased PSD-95. A beta modifies the conformation of the NMDAR C-terminal domain (CTD) and its interaction with protein phosphatase 1 (PP1), producing synaptic weakening. Higher endogenous levels or overexpression of PSD-95 block A beta-induced effects on the NMDAR CTD conformation, its interaction with PP1, and synaptic weakening. Our results indicate that increased PSD-95 protects synapses from A beta toxicity, suggesting that low levels of synaptic PSD-95 may be a molecular sign indicating synapse vulnerability to A beta. Importantly, pharmacological inhibition of its depalmitoylation increases PSD-95 at synapses and rescues deficits caused by A beta, possibly opening a therapeutic avenue against Alzheimer's disease.

Automated summary

The study found that increased PSD-95 can protect synapses from the toxic effects of A beta, suggesting that low levels of PSD-95 may be a molecular sign of synapse vulnerability to A beta. Inhibition of PSD-95 depalmitoylation pharmacologically may offer a therapeutic avenue against Alzheimer's disease.